8-K: Protagenic Therapeutics Faces Nasdaq Delisting Risk Due to Low Share Price

Protagenic Therapeutics has received a notice from Nasdaq for failing to maintain the minimum bid price of $1.00 per share, placing its listing at risk.

Summary

• Protagenic Therapeutics received a notification from Nasdaq on July 24, 2024, stating that the company is not in compliance with the minimum bid price requirement of $1.00 per share.
• The company's stock price has been below $1.00 for 30 consecutive business days, triggering the deficiency notice.
• Protagenic has 180 calendar days, until January 20, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.
• If the company fails to regain compliance by January 20, 2025, it may be eligible for an additional 180 days if it meets other listing requirements, excluding the bid price.
• Failure to regain compliance within the allotted time could lead to the delisting of Protagenic's common stock from the Nasdaq Capital Market.
• The company may appeal a delisting determination, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the potential for delisting, which is a major concern for investors.

Positives

• The company has been granted 180 days to regain compliance with the minimum bid price requirement.
• There is a possibility of an additional 180-day extension if other listing requirements are met.
• The company has the option to appeal a delisting determination.

Negatives

• The company's stock price has been below the required $1.00 minimum for 30 consecutive business days.
• The company is at risk of being delisted from the Nasdaq Capital Market if it fails to regain compliance.
• There is no guarantee that an appeal against delisting would be successful.

Risks

• The primary risk is the potential delisting of Protagenic's stock from the Nasdaq Capital Market.
• The company's ability to raise capital may be negatively impacted if it is delisted.
• The company's reputation and investor confidence could be damaged by a delisting.

Future Outlook

The company must regain compliance with Nasdaq's minimum bid price requirement by January 20, 2025, or potentially face delisting. They may have an additional 180 days if other requirements are met.

Industry Context

This announcement highlights the challenges faced by companies with low stock prices in maintaining their listing on major exchanges like Nasdaq. It is not uncommon for companies to receive deficiency notices for failing to meet minimum bid price requirements.

Comparison to Industry Standards

• Many small-cap and biotech companies face similar challenges in maintaining their stock price above the minimum bid price required by exchanges like Nasdaq.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced similar delisting risks due to low stock prices.
• The 180-day compliance period is a standard procedure for Nasdaq, allowing companies time to rectify the deficiency.

Stakeholder Impact

• Shareholders face the risk of losing their investment if the company is delisted.
• Employees may experience uncertainty about the company's future.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• The company must take steps to increase its stock price to at least $1.00 for ten consecutive business days.
• The company may need to consider a reverse stock split or other measures to regain compliance.
• The company may need to prepare for a potential appeal process if it fails to regain compliance.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, PTIX, deficiency letter